Caseware UK (AP4) 2022.0.179 2022.0.179 2023-04-302023-04-30truetrueNo description of principal activity2022-05-0111 05825135 2022-05-01 2023-04-30 05825135 2021-05-01 2022-04-30 05825135 2023-04-30 05825135 2022-04-30 05825135 c:Director1 2022-05-01 2023-04-30 05825135 c:EntityHasNeverTraded 2022-05-01 2023-04-30 05825135 c:AuditExempt-NoAccountantsReport 2022-05-01 2023-04-30 05825135 c:FullAccounts 2022-05-01 2023-04-30 05825135 c:PrivateLimitedCompanyLtd 2022-05-01 2023-04-30 05825135 c:Micro-entities 2022-05-01 2023-04-30 iso4217:GBP xbrli:pure

Registered number: 05825135









REMEDY MEDICAL SOLUTIONS LIMITED







UNAUDITED

FINANCIAL STATEMENTS

INFORMATION FOR FILING WITH THE REGISTRAR

FOR THE YEAR ENDED 30 APRIL 2023

 
REMEDY MEDICAL SOLUTIONS LIMITED
REGISTERED NUMBER: 05825135

BALANCE SHEET
AS AT 30 APRIL 2023

2023
2022
£
£


Current assets
100
100

Net current assets
 
 
100
 
 
100

Total assets less current liabilities
100
100


Net assets
100
100



Capital and reserves
100
100


Notes


General information

Remedy Medical Solutions Limited is a private company, limited by shares and incorporated in England and Wales, United Kingdom, with a registration number 05825135. The address of the registered office is Connaught House 1st Flor, 112-120 High Road, Loughton, Essex, IG10 4HJ.


Average number of employees

The average monthly number of employees, including directors, during the year was 1 (2022 - 1).

The Company was entitled to exemption from audit under section 480 of the Companies Act 2006.

The members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

These financial statements have been prepared in accordance with the provisions applicable to entities subject to the micro-entities' regime.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf on 6 March 2024.




D Sugarman
Director

The notes on  form part of these financial statements.

Page 1